472 related articles for article (PubMed ID: 19559113)
1. Use of MDCK cells for production of live attenuated influenza vaccine.
Liu J; Shi X; Schwartz R; Kemble G
Vaccine; 2009 Oct; 27(46):6460-3. PubMed ID: 19559113
[TBL] [Abstract][Full Text] [Related]
2. Production of cell culture (MDCK) derived live attenuated influenza vaccine (LAIV) in a fully disposable platform process.
George M; Farooq M; Dang T; Cortes B; Liu J; Maranga L
Biotechnol Bioeng; 2010 Aug; 106(6):906-17. PubMed ID: 20589670
[TBL] [Abstract][Full Text] [Related]
3. Comparative study of influenza virus replication in Vero and MDCK cell lines.
Youil R; Su Q; Toner TJ; Szymkowiak C; Kwan WS; Rubin B; Petrukhin L; Kiseleva I; Shaw AR; DiStefano D
J Virol Methods; 2004 Sep; 120(1):23-31. PubMed ID: 15234806
[TBL] [Abstract][Full Text] [Related]
4. Production of influenza virus in serum-free mammalian cell cultures.
Merten OW; Manuguerra JC; Hannoun C; van der Werf S
Dev Biol Stand; 1999; 98():23-37; discussion 73-4. PubMed ID: 10494957
[TBL] [Abstract][Full Text] [Related]
5. Development of cell culture (MDCK) live cold-adapted (CA) attenuated influenza vaccine.
Ghendon YZ; Markushin SG; Akopova II; Koptiaeva IB; Nechaeva EA; Mazurkova LA; Radaeva IF; Kolokoltseva TD
Vaccine; 2005 Sep; 23(38):4678-84. PubMed ID: 16026905
[TBL] [Abstract][Full Text] [Related]
6. Growth and immunogenicity of influenza viruses cultivated in Vero or MDCK cells and in embryonated chicken eggs.
Govorkova EA; Kodihalli S; Alymova IV; Fanget B; Webster RG
Dev Biol Stand; 1999; 98():39-51; discussion 73-4. PubMed ID: 10494958
[TBL] [Abstract][Full Text] [Related]
7. The growth of attenuated influenza vaccine donor strains in continuous cell lines.
Audsley JM; Tannock GA
J Virol Methods; 2005 Feb; 123(2):187-93. PubMed ID: 15620401
[TBL] [Abstract][Full Text] [Related]
8. Adaptation of a Madin-Darby canine kidney cell line to suspension growth in serum-free media and comparison of its ability to produce avian influenza virus to Vero and BHK21 cell lines.
van Wielink R; Kant-Eenbergen HC; Harmsen MM; Martens DE; Wijffels RH; Coco-Martin JM
J Virol Methods; 2011 Jan; 171(1):53-60. PubMed ID: 20933017
[TBL] [Abstract][Full Text] [Related]
9. Development of a Vero cell-derived influenza whole virus vaccine.
Kistner O; Barrett PN; Mundt W; Reiter M; Schober-Bendixen S; Eder G; Dorner F
Dev Biol Stand; 1999; 98():101-10; discussion 111. PubMed ID: 10494963
[TBL] [Abstract][Full Text] [Related]
10. Phenotypic properties resulting from directed gene segment reassortment between wild-type A/Sydney/5/97 influenza virus and the live attenuated vaccine strain.
Parks CL; Latham T; Cahill A; O'neill RE; Passarotti CJ; Buonagurio DA; Bechert TM; D'Arco GA; Neumann G; Destefano J; Arendt HE; Obregon J; Shutyak L; Hamm S; Sidhu MS; Zamb TJ; Udem SA
Virology; 2007 Oct; 367(2):275-87. PubMed ID: 17599381
[TBL] [Abstract][Full Text] [Related]
11. Comparison of egg and high yielding MDCK cell-derived live attenuated influenza virus for commercial production of trivalent influenza vaccine: in vitro cell susceptibility and influenza virus replication kinetics in permissive and semi-permissive cells.
Hussain AI; Cordeiro M; Sevilla E; Liu J
Vaccine; 2010 May; 28(22):3848-55. PubMed ID: 20307595
[TBL] [Abstract][Full Text] [Related]
12. Evaluation of immune responses to inactivated influenza vaccines prepared in embryonated chicken eggs and MDCK cells in a mouse model.
Nerome K; Kumihashi H; Nerome R; Hiromoto Y; Yokota Y; Ueda R; Omoe K; Chiba M
Dev Biol Stand; 1999; 98():53-63; discussion 73-4. PubMed ID: 10494959
[TBL] [Abstract][Full Text] [Related]
13. Microcarrier-based MDCK cell culture system for the production of influenza H5N1 vaccines.
Hu AY; Weng TC; Tseng YF; Chen YS; Wu CH; Hsiao S; Chou AH; Chao HJ; Gu A; Wu SC; Chong P; Lee MS
Vaccine; 2008 Oct; 26(45):5736-40. PubMed ID: 18761387
[TBL] [Abstract][Full Text] [Related]
14. Wave microcarrier cultivation of MDCK cells for influenza virus production in serum containing and serum-free media.
Genzel Y; Olmer RM; Schäfer B; Reichl U
Vaccine; 2006 Aug; 24(35-36):6074-87. PubMed ID: 16781022
[TBL] [Abstract][Full Text] [Related]
15. Shedding and immunogenicity of live attenuated influenza vaccine virus in subjects 5-49 years of age.
Block SL; Yogev R; Hayden FG; Ambrose CS; Zeng W; Walker RE
Vaccine; 2008 Sep; 26(38):4940-6. PubMed ID: 18662737
[TBL] [Abstract][Full Text] [Related]
16. High-yield production of a stable Vero cell-based vaccine candidate against the highly pathogenic avian influenza virus H5N1.
Zhou F; Zhou J; Ma L; Song S; Zhang X; Li W; Jiang S; Wang Y; Liao G
Biochem Biophys Res Commun; 2012 May; 421(4):850-4. PubMed ID: 22554519
[TBL] [Abstract][Full Text] [Related]
17. [Development of a novel influenza vaccine derived from a continuous cell line].
Kistner O; Barrett N; Mundt W; Reiter M; Schober-Bendixen S; Eder G; Dorner F
ALTEX; 2001; 18(1):50-4. PubMed ID: 11248852
[TBL] [Abstract][Full Text] [Related]
18. High titer growth of human and avian influenza viruses in an immortalized chick embryo cell line without the need for exogenous proteases.
Smith KA; Colvin CJ; Weber PS; Spatz SJ; Coussens PM
Vaccine; 2008 Jul; 26(29-30):3778-82. PubMed ID: 18524432
[TBL] [Abstract][Full Text] [Related]
19. Productivity, apoptosis, and infection dynamics of influenza A/PR/8 strains and A/PR/8-based reassortants.
Isken B; Genzel Y; Reichl U
Vaccine; 2012 Jul; 30(35):5253-61. PubMed ID: 22698452
[TBL] [Abstract][Full Text] [Related]
20. Continuous cell lines as a production system for influenza vaccines.
Genzel Y; Reichl U
Expert Rev Vaccines; 2009 Dec; 8(12):1681-92. PubMed ID: 19943763
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
